News & Updates

In the updated analysis of the phase III EMERALD trial, the next-generation oral SERD* elacestrant continued to show favourable signals for the treatment of ER+/HER2– metastatic breast cancer (mBC).

In the final overall survival (OS) analysis of the phase III PAOLA-1*/ENGOT-ov25 trial, the addition of olaparib to bevacizumab provided a survival benefit for women with newly diagnosed advanced ovarian cancer with HRD**-positive (HRD+) tumours.

In low- and middle-income countries (LMICs), there appears to be a long interval between the first onset of breast cancer symptoms and presentation to a healthcare provider, reports a recent study.

Human papillomavirus (HPV) self-sampling for cervical cancer screening is highly acceptable among Singaporean women, with the strategy deemed accurate and easy to perform, a study has found.

The first-in-class KRAS^G12C inhibitor sotorasib significantly improved progression-free survival (PFS) in patients with previously treated non-small cell lung cancer (NSCLC) with KRAS^G12C mutations, according to results of the phase III CodeBreaK 200 trial presented at ESMO 2022.

In cancer patients, the presence of diabetes appears to aggravate the likelihood of developing a secondary malignancy or death, reports a recent Japan study.

Prophylactic granulocyte-colony stimulating factor (G-CSF) results in a significant decrease both in the rate of febrile neutropaenia (FN) and duration of hospitalization for FN in breast cancer patients treated with docetaxel-based chemotherapy regimens (DBRs), according to a recent study.